Literature DB >> 14310744

(CROSS-IMMUNITY STUDIES ON VIRULENT STRAINS OF LEPTOSPIRES BELONGING TO DIFFERENT SEROTYPES.)

F KEMENES.   

Abstract

Keywords:  EXPERIMENTAL LAB STUDY; GUINEA PIGS; IMMUNITY; LEPTOSPIRA; LEPTOSPIROSIS

Mesh：

Year:  1964        PMID： 14310744

Source DB:  PubMed          Journal:  Z Immunitats Allergieforsch        ISSN： 0372-9001


× No keyword cloud information.
  7 in total

1.  [Requirements in research on leptospirosis].

Authors: 
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

2.  Comparative tests with formolized and irradiated vaccines against leptospirosis.

Authors:  B Babudieri; M Castelli; F Pisoni
Journal:  Bull World Health Organ       Date:  1973-05       Impact factor: 9.408

Review 3.  Research needs in leptospirosis.

Authors:  M Abdussalam; A D Alexander; B Babudieri; K Bögel; C Borg-Petersen; S Faine; E Kmety; C Lataste-Dorolle; L H Turner
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

4.  Cross-neutralization of leptospiral hemolysins from different serotypes.

Authors:  A D Alexander; G Wood; F Yancey; R J Byrne; R H Yager
Journal:  Infect Immun       Date:  1971-08       Impact factor: 3.441

5.  Purine analogue sensitivity and lipase activity of leptospires.

Authors:  R C Johnson; V G Harris
Journal:  Appl Microbiol       Date:  1968-10

6.  2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention.

Authors:  J E Sykes; K Hartmann; K F Lunn; G E Moore; R A Stoddard; R E Goldstein
Journal:  J Vet Intern Med       Date:  2010-12-13       Impact factor: 3.333

7.  New strategies for Leptospira vaccine development based on LPS removal.

Authors:  Fabiana Lauretti-Ferreira; Paloma L D Silva; Naiara M Alcântara; Bruna F Silva; Isabele Grabher; Gisele O Souza; Erika Nakajima; Milena A Akamatsu; Silvio A Vasconcellos; Patricia A E Abreu; Eneas Carvalho; Elizabeth A L Martins; Paulo L Ho; Josefa B da Silva
Journal:  PLoS One       Date:  2020-03-27       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.